ArticleNature communications2020
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report.
Open access · goldAbstract readCase Reports
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 4 pooled it
2.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 4 syntheses or guidelines pooled it, 130 citations in OpenAlex.
- COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.JAMA network open · 2023Pooled it
- Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022).Transplantation and cellular therapy · 2022Guideline
- COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review.Clinical immunology (Orlando, Fla.) · 2022Pooled it
- 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy.European journal of cancer (Oxford, England : 1990) · 2021Guideline
- Extensive evolution and T cell escape by SARS-CoV-2 in a 2.5-year persistent infection of an immunocompromised host.iScience · 2026Article
- Signatures of omicron-like adaptation in early SARS-CoV-2 variants and chronic infection.Cell reports · 2025Article
- Effectiveness of early intervention and combination treatment with monoclonal antibodies and antivirals in oncohematological patients with SARS-CoV-2: a retrospective experience.Frontiers in immunology · 2025Article
- SARS-CoV-2 detection via metagenomic next-generation sequencing of bronchoalveolar lavage fluid/sputum in lymphoma patients receiving B-cell-depleting therapy: a case report of two cases.Frontiers in medicine · 2025Article
- Identification of Natural Compounds as Potential COVID-19 Main Protease (Mpro) Inhibitors: A Comprehensive Study andCurrent pharmaceutical design · 2025Review
- Stuck in pandemic uncertainty: a review of the persistent effects of COVID-19 infection in immune-deficient people.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2024Review
- Novel immunomodulatory properties of adenosine analogs promote their antiviral activity against SARS-CoV-2.EMBO reports · 2024Article
- From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2.Vaccines · 2024Review
- Case report: Rapidly progressive neurocognitive disorder with a fatal outcome in a patient with PU.1 mutated agammaglobulinemia.Frontiers in immunology · 2024Article
- Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Rapid Response to Remdesivir in Hospitalised COVID-19 Patients: A Propensity Score Weighted Multicentre Cohort Study.Infectious diseases and therapy · 2023Article
- Article
- T Cell Abnormalities in X-Linked Agammaglobulinaemia: an Updated Review.Clinical reviews in allergy & immunology · 2023Review
- Age-associated B cells predict impaired humoral immunity after COVID-19 vaccination in patients receiving immune checkpoint blockade.Nature communications · 2023Article
- COVID-19 relapse associated with SARS-CoV-2 evasion from CD4iScience · 2023Article
- Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
51 authors at 15 institutions in 4 countries.
Matthew S BucklandDepartment of Clinical Immunology, Barts Health, London, UK. m.buckland@ucl.ac.uk.ORCID 0000-0002-5646-4707
James B GallowayCentre for Rheumatic Diseases, King's College London, London, UK.
Caoimhe Nic FhogartaighDepartment of Infection, Barts Health NHS Trust, London, UK.
Luke MeredithDepartment of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Nicholas M ProvinePeter Medawar Building for Pathogen Research, South Parks Rd, Oxford, OX1 3SY, UK.
Stuart BloorCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK.
Ane OgbePeter Medawar Building for Pathogen Research, South Parks Rd, Oxford, OX1 3SY, UK.ORCID 0000-0001-7774-7215
Wioleta M ZelekSystems Immunity Institute and Dementia Research Institute, Cardiff University, Cardiff, UK.
Anna SmielewskaDivision of Virology, Department of Pathology, University of Cambridge, Addenbrookes Hospital, Cambridge, UK.
Anna YakovlevaDepartment of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Tiffeney MannMedical Research Council Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge, CB2 1QW, UK.
Laura BergamaschiCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK.
Lorinda TurnerCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK.
Frederica MesciaCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK.ORCID 0000-0002-2759-4027
Erik J M ToonenR&D Department, Hycult Biotechnology, Frontstraat 2A, 5405 PB, Uden, The Netherlands.ORCID 0000-0001-9039-635X
Carl-Philipp HacksteinPeter Medawar Building for Pathogen Research, South Parks Rd, Oxford, OX1 3SY, UK.
Hossain Delowar AktherPeter Medawar Building for Pathogen Research, South Parks Rd, Oxford, OX1 3SY, UK.
Vinicius Adriano VieiraPeter Medawar Building for Pathogen Research, South Parks Rd, Oxford, OX1 3SY, UK.ORCID 0000-0002-4901-0424
Lourdes Ceron-GutierrezDepartment of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.
Jimstan PeriselnerisRespiratory Department, King's College Hospital NHS Foundation Trust, UK. Department of Clinical Virology, Addenbrookes, UK.
Sorena Kiani-AlikhanDepartment of Clinical Immunology, Barts Health, London, UK.ORCID 0000-0002-1299-4415
Sofia GrigoriadouDepartment of Clinical Immunology, Barts Health, London, UK.
Devan VaghelaDepartment of Infectious Diseases, Cambridge University Hospitals NHS Trust, Cambridge, UK.
Sara E LearDepartment of Immunology, Cambridge University Hospitals NHS Trust, Cambridge, UK.
M Estée TörökCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK.
William L HamiltonCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK.
Joanne StocktonInstitute of Microbiology and Infection, University of Birmingham, Birmingham, UK.
Josh QuickInstitute of Microbiology and Infection, University of Birmingham, Birmingham, UK.
Peter NelsonBelfast Health and Social Care Trust, Belfast, Northern Ireland, UK.
Michael HunterBelfast Health and Social Care Trust, Belfast, Northern Ireland, UK.
Tanya I CoulterBelfast Health and Social Care Trust, Belfast, Northern Ireland, UK.
Lisa DevlinBelfast Health and Social Care Trust, Belfast, Northern Ireland, UK.
CITIID-NIHR COVID-19 BioResource Collaboration
MRC-Toxicology Unit COVID-19 Consortium
John R BradleyNIHR BioResource and NIHR Cambridge Biomedical Research Centre, Cambridge Biomedical Campus, Cambridge, UK.
Kenneth G C SmithCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK.
Willem H OuwehandDepartment of Haematology, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.ORCID 0000-0002-7744-1790
Lise EstcourtNHS Blood and Transplant, Oxford, UK.
Heli HarvalaNHS Blood and Transplant, London, UK.
David J RobertsNHS Blood and Transplant, Oxford, UK.
Ian B WilkinsonDepartment of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
Nick ScreatonRadiology, Papworth Hospital, Cambridge, UK.
Nicholas LomanInstitute of Microbiology and Infection, University of Birmingham, Birmingham, UK.
Rainer DoffingerRespiratory Department, King's College Hospital NHS Foundation Trust, UK. Department of Clinical Virology, Addenbrookes, UK.
Paul A LyonsCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK.ORCID 0000-0001-7035-8997
B Paul MorganSystems Immunity Institute and Dementia Research Institute, Cardiff University, Cardiff, UK.
Ian G GoodfellowDepartment of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Paul KlenermanPeter Medawar Building for Pathogen Research, South Parks Rd, Oxford, OX1 3SY, UK.
Paul J LehnerCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK.ORCID 0000-0001-9383-1054
Nicholas J MathesonCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK. njm25@cam.ac.uk.ORCID 0000-0002-3318-1851
James E D ThaventhiranCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK. jedt2@cam.ac.uk.ORCID 0000-0001-8616-074X
University of Cambridge · GBUniversity of Oxford · GBNHS Blood and Transplant · GBBarts Health NHS Trust · GBBelfast Health and Social Care Trust · GBCambridge University Hospitals NHS Foundation Trust · GBUniversity of Birmingham · GBKing's College Hospital NHS Foundation Trust · GBUK Dementia Research Institute · GBAddenbrooke's Hospital · GBHycult Biotech (Netherlands) · NLKing's College London · GBMRC Laboratory of Molecular Biology · GBNIHR Cambridge Biomedical Research CentrePapworth Hospital · GB
Funding
Department of HealthHCRW_ HF-19-1595Medical Research Council MC_EX_MR/S300011/1Medical Research Council MC_UU_00025/12Medical Research Council MR/J014370/1Medical Research Council MR/L006197/1Medical Research Council MR/M501621/1Medical Research Council MR/P008801/1Medical Research Council MR/S035362/1Medical Research Council MR/V011561/1Medical Research Council MR/V028448/1Medical Research Council RG95376Wellcome Trust 109965/Z/15/ZWellcome Trust 200871/Z/16/ZWellcome Trust 206298/B/17/ZWellcome Trust 207498/Z/17/ZWellcome Trust 210688/Z/18/ZWellcome Trust WT109965MA
Abstract
The response to the coronavirus disease 2019 (COVID-19) pandemic has been hampered by lack of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral therapy. Here we report the use of remdesivir in a patient with COVID-19 and the prototypic genetic antibody deficiency X-linked agammaglobulinaemia (XLA). Despite evidence of complement activation and a robust T cell response, the patient developed persistent SARS-CoV-2 pneumonitis, without progressing to multi-organ involvement. This unusual clinical course is consistent with a contribution of antibodies to both viral clearance and progression to severe disease. In the absence of these confounders, we take an experimental medicine approach to examine the in vivo utility of remdesivir. Over two independent courses of treatment, we observe a temporally correlated clinical and virological response, leading to clinical resolution and viral clearance, with no evidence of acquired drug resistance. We therefore provide evidence for the antiviral efficacy of remdesivir in vivo, and its potential benefit in selected patients.
Indexed as
Adenosine MonophosphateAdultAlanineAntiviral AgentsCOVID-19FeverHumansImmunity, HumoralLymphocyte CountMaleSARS-CoV-2Treatment OutcomeAdenosine MonophosphateAlanineAntiviral Agentsremdesivir
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.